$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000162828019011753 Filed on September 16, 2019

Income Statement

Concept	2019 Q3	2018 Q3
Revenue	$6.737M	$6.225M
YoY Change	8.22%	23.68%
Cost Of Revenue	$3.752M	$3.083M
YoY Change	21.7%	16.69%
Gross Profit	$2.985M	$3.142M
YoY Change	-5.0%	31.41%
Gross Profit Margin	44.31%	50.47%
Selling, General & Admin	$2.296M	$1.573M
YoY Change	45.96%	-16.86%
% of Gross Profit	76.92%	50.06%
Research & Development	$1.303M	$1.088M
YoY Change	19.76%	-2.68%
% of Gross Profit	43.65%	34.63%
Depreciation & Amortization	$145.0K	$111.0K
YoY Change	30.63%	208.33%
% of Gross Profit	4.86%	3.53%
Operating Expenses	$7.351M	$5.744M
YoY Change	27.98%	1.63%
Operating Profit	-$614.0K	$481.0K
YoY Change	-227.65%	-177.71%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$12.00K	$1.000K
YoY Change	-1300.0%	-101.96%
Pretax Income	-$626.0K	$482.0K
YoY Change	-229.88%	-171.94%
Income Tax	$15.00K	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$641.0K	$483.0K
YoY Change	-232.71%	-171.66%
Net Earnings / Revenue	-9.51%	7.76%
Basic Earnings Per Share	-$0.06	$0.04
Diluted Earnings Per Share	-$0.06	$0.04
COMMON SHARES
Basic Shares Outstanding	11.62M shares	11.01M shares
Diluted Shares Outstanding	11.62M shares	12.62M shares

Balance Sheet

Concept	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.200M	$1.020M
YoY Change	115.69%	137.21%
Cash & Equivalents	$2.202M	$1.000M
Short-Term Investments
Other Short-Term Assets	$260.0K	$250.0K
YoY Change	4.0%	-30.56%
Inventory
Prepaid Expenses
Receivables	$3.891M	$3.769M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$6.349M	$5.031M
YoY Change	26.2%	45.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.113M	$2.425M
YoY Change	28.37%	16.36%
Goodwill	$669.0K	$669.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$128.0K	$116.0K
YoY Change	10.34%	8.41%
Total Long-Term Assets	$7.013M	$3.360M
YoY Change	108.72%	11.63%
TOTAL ASSETS
Total Short-Term Assets	$6.349M	$5.031M
Total Long-Term Assets	$7.013M	$3.360M
Total Assets	$13.36M	$8.391M
YoY Change	59.24%	29.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.725M	$2.119M
YoY Change	28.6%	22.34%
Accrued Expenses	$770.0K	$366.0K
YoY Change	110.38%	-33.58%
Deferred Revenue	$3.969M	$4.263M
YoY Change	-6.9%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.00K	$140.0K
YoY Change	-92.86%	366.67%
Total Short-Term Liabilities	$7.930M	$6.885M
YoY Change	15.18%	14.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$150.0K
YoY Change	-100.0%	400.0%
Other Long-Term Liabilities	$151.0K	$151.0K
YoY Change	0.0%	-3.82%
Total Long-Term Liabilities	$151.0K	$151.0K
YoY Change	0.0%	-3.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.930M	$6.885M
Total Long-Term Liabilities	$151.0K	$151.0K
Total Liabilities	$11.63M	$7.789M
YoY Change	49.36%	26.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.30M	-$70.34M
YoY Change	1.36%	0.46%
Common Stock	$73.07M	$72.20M
YoY Change	1.2%	0.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$1.252M
YoY Change		0.0%
Treasury Stock Shares		269.7K shares
Shareholders Equity	$1.728M	$603.0K
YoY Change
Total Liabilities & Shareholders Equity	$13.36M	$8.391M
YoY Change	59.24%	29.75%

Cashflow Statement

Concept	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$641.0K	$483.0K
YoY Change	-232.71%	-171.66%
Depreciation, Depletion And Amortization	$145.0K	$111.0K
YoY Change	30.63%	208.33%
Cash From Operating Activities	-$279.0K	$336.0K
YoY Change	-183.04%	-117.25%
INVESTING ACTIVITIES
Capital Expenditures	$749.0K	$211.0K
YoY Change	254.98%	-76.81%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$749.0K	-$211.0K
YoY Change	254.98%	-76.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$7.000K	$35.00K
YoY Change	-120.0%	-600.0%
NET CHANGE
Cash From Operating Activities	-$279.0K	$336.0K
Cash From Investing Activities	-$749.0K	-$211.0K
Cash From Financing Activities	-$7.000K	$35.00K
Net Change In Cash	-$1.035M	$160.0K
YoY Change	-746.88%	-105.58%
FREE CASH FLOW
Cash From Operating Activities	-$279.0K	$336.0K
Capital Expenditures	$749.0K	$211.0K
Free Cash Flow	-$1.028M	$125.0K
YoY Change	-922.4%	-104.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	16000	USD
CY2019Q3	csbr	Assetsin Progress Gross AssetsinProgressGross	619000	USD
CY2018Q3	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	11000	USD
CY2018Q3	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
CY2019Q3	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	42000	USD
CY2018Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2019Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	98000	USD
CY2019Q3	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2018Q3	csbr	Reversalof Provisionfor Doubtful Accounts ReversalofProvisionforDoubtfulAccounts	0	USD
CY2019Q3	csbr	Reversalof Provisionfor Doubtful Accounts ReversalofProvisionforDoubtfulAccounts	6000	USD
CY2019Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	0	USD
CY2019Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P4Y9M50D
CY2019Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	2083	shares
CY2019Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	0	USD
CY2019Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	1671440	shares
CY2019Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	1669773	shares
CY2019Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	11.50
CY2019Q3	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Canceled SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCanceled	0	USD
CY2019Q3	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised	0	USD
CY2019Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	-1600000	USD
CY2019Q3	dei	Amendment Flag AmendmentFlag	false
CY2019Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2019Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2019Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	1982000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1180000	USD
CY2019Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	1972000	USD
CY2019Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4399000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	770000	USD
CY2019Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3919000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2074000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2256000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72924000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	73055000	USD
CY2019Q3	dei	Document Period End Date DocumentPeriodEndDate	2019-07-31
CY2019Q3	dei	Document Type DocumentType	10-Q
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4377000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3891000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2807000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2725000	USD
CY2019Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11619538	shares
CY2019Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q3	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2019Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	83000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	131000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	22000	USD
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	28000	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4691379	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4044648	shares
CY2019Q2	us-gaap	Assets Assets	11265000	USD
CY2019Q3	us-gaap	Assets Assets	13362000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	7922000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	6349000	USD
CY2019Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	16000	USD
CY2019Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	9000	USD
CY2018Q3	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	249000	USD
CY2019Q3	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2019Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1104000	USD
CY2019Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1117000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3237000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2202000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1006000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1166000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3237000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2202000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	160000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1035000	USD
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11619538	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11619538	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11619538	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11619538	shares
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2019Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4022000	USD
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3969000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4022000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3969000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3083000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3752000	USD
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	851000	USD
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q3	us-gaap	Depreciation Depreciation	111000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	145000	USD
CY2018Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	118000	USD
CY2019Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2019Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	366000	USD
CY2019Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	366000	USD
CY2019Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	142000	USD
CY2019Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	178000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1055000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1426000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	669000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	482000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-626000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-43000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-82000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-148000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-480000	USD
CY2018Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-203000	USD
CY2019Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-410000	USD
CY2018Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-441000	USD
CY2019Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-53000	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-41000	USD
CY2019Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-52000	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-151000	USD
CY2019Q3	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1605740	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	8000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4400000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1419000	USD
CY2019Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2019Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0725
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11180000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1404000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1445000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1471000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1041000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	9027000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	11634000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11265000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13362000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8025000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7930000	USD
CY2019Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3358000	USD
CY2019Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3455000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-211000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-749000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	336000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-279000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	482000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-641000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	482000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-641000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	5744000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	7351000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	481000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-614000	USD
CY2018Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	188000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	239000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	457000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3553000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3103000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	151000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	151000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	211000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	749000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	308000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	256000	USD
CY2018Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2019Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4620000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5369000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2546000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3113000	USD
CY2018Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2019Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1088000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1303000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70698000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71339000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71300000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6225000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6737000	USD
CY2018Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3205000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	518000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	870000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	75000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	131000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8440
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0000
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0282
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0000
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2143231	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.74
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	6668	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	40000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.18
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14557000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8836000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2423626	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2374875	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.19
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.08
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	8836000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2374875	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.08
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	7500	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2019Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.24
CY2019Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.20
CY2019Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.00
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8469000	USD
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y5M24D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M19D
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M50D
CY2019Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	3000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	602000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	2238000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1728000	USD
CY2019Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2417000	USD
CY2019Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	1947000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2019Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12618021	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11619538	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11012281	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11619538	shares

Files In Submission

Name	View Source	Status
0001628280-19-011753-index-headers.html	Edgar Link	pending
0001628280-19-011753-index.html	Edgar Link	pending
0001628280-19-011753.txt	Edgar Link	pending
0001628280-19-011753-xbrl.zip	Edgar Link	pending
csbr-20190731.xml	Edgar Link	completed
csbr-20190731.xsd	Edgar Link	pending
csbr-20190731_cal.xml	Edgar Link	unprocessable
csbr-20190731_def.xml	Edgar Link	unprocessable
csbr-20190731_lab.xml	Edgar Link	unprocessable
csbr-20190731_pre.xml	Edgar Link	unprocessable
csbr10-q7312019.htm	Edgar Link	pending
csbrq1731201910-qex311.htm	Edgar Link	pending
csbrq1731201910-qex312.htm	Edgar Link	pending
csbrq1731201910-qex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2019 Q3 Form 10-Q Financial Statement

#000162828019011753 Filed on September 16, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2019 Q3 Form 10-Q Financial Statement

#000162828019011753 Filed on September 16, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr